PMID- 2556717
OWN - NLM
STAT- MEDLINE
DCOM- 19900119
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 86
IP  - 23
DP  - 1989 Dec
TI  - Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte 
      transformation.
PG  - 9558-62
AB  - Epstein-Barr virus (EBV) efficiently transforms B lymphocytes to perpetual 
      proliferation. The EBV laboratory strain P3HR-1 is transformation-incompetent and 
      lacks a DNA segment that includes the EBV nuclear antigen 2 (EBNA-2) gene and a 
      portion of the EBNA leader protein (EBNA-LP) gene. These two genes are expressed 
      in transformed B lymphocytes. Recombinant transformation-competent EBVs were 
      produced by transfecting P3HR-1-infected cells with a cosmid containing the DNA 
      deleted in P3HR-1. Deletion of 105 nucleotides from the middle of the EBNA-2 gene 
      had no discernible affect on transformation. Two larger EBNA-2 deletions 
      abolished transformation but did not affect EBNA-2 nuclear localization. Two 
      naturally occurring EBV variants (EBV types 1 and 2) differ extensively in their 
      growth-transformation phenotype and in their EBNA-LP, EBNA-2, and EBNA-3A, -3B, 
      and -3C genes. Recombinant P3HR-1 carrying EBV-1 EBNA-2 has many of the EBV-1 in 
      vitro growth-transforming effects; recombinant P3HR-1, isogenic except for EBV-2 
      EBNA-2, has many of the EBV-2 growth-transforming effects including slow 
      emergence of transformants, growth in tight clumps with few surrounding viable 
      cells, and early sensitivity to dilution with fresh medium. Thus, EBNA-2 is an 
      essential molecule in lymphocyte growth transformation by EBV and a major 
      determinant of the differences between EBV-1 and EBV-2 in lymphocyte growth 
      transformation.
FAU - Cohen, J I
AU  - Cohen JI
AD  - Department of Medicine, Harvard Medical School, Boston, MA 02115.
FAU - Wang, F
AU  - Wang F
FAU - Mannick, J
AU  - Mannick J
FAU - Kieff, E
AU  - Kieff E
LA  - eng
GR  - CA01395/CA/NCI NIH HHS/United States
GR  - CA01417/CA/NCI NIH HHS/United States
GR  - CA47006/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Antigens, Viral)
RN  - 0 (Epstein-Barr Virus Nuclear Antigens)
RN  - 0 (Viral Matrix Proteins)
SB  - IM
MH  - Antigens, Viral/*genetics/immunology
MH  - B-Lymphocytes/*immunology
MH  - Cell Line
MH  - Chromosome Deletion
MH  - Epstein-Barr Virus Nuclear Antigens
MH  - Genes, Viral
MH  - Herpesvirus 4, Human/genetics/*immunology
MH  - Humans
MH  - Immunoblotting
MH  - *Lymphocyte Activation
MH  - Plasmids
MH  - Viral Matrix Proteins/genetics
PMC - PMC298536
EDAT- 1989/12/01 00:00
MHDA- 1989/12/01 00:01
PMCR- 1990/06/01
CRDT- 1989/12/01 00:00
PHST- 1989/12/01 00:00 [pubmed]
PHST- 1989/12/01 00:01 [medline]
PHST- 1989/12/01 00:00 [entrez]
PHST- 1990/06/01 00:00 [pmc-release]
AID - 10.1073/pnas.86.23.9558 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62. doi: 10.1073/pnas.86.23.9558.